**UNITED      STATES**

**SECURITIES      AND EXCHANGE COMMISSION**

**WASHINGTON,      D.C. 20549**

**FORM      10-Q**

| x | QUARTERLY                REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF                1934. |
|---|------------------------------------------------------------------------------------------------------------------|

| o | TRANSITION                REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE                ACT |
|---|-----------------------------------------------------------------------------------------------|

**NUTRA      PHARMA CORP.**

| **California**                                               | **91-2021600**                                      |
|--------------------------------------------------------------|-----------------------------------------------------|
| (State                or Other Jurisdiction of Organization) | (IRS                Employer Identification Number) |

**791      Park of Commerce Blvd, Suite 300, Boca Raton, FL 33487**

**(954)      509-0911**

| Large                accelerated filer o | Accelerated                filer o         |
|------------------------------------------|--------------------------------------------|
| Non-accelerated                filer o   | Smaller                reporting company x |

----

| PART                I. FINANCIAL INFORMATION                                                                                                                                                                                                              |   |   |        |   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|--------|--------|
|                                                                                                                                                                                                                                                 |   |   |   |   |
| Item                1. Financial Statements                                                                                                                                                                                                               |   |   | 3      |   |
|                                                                                                                                                                                                                                                 |   |   |   |   |
| Consolidated                Balance Sheets as of September 30, 2008 (Unaudited) and December                31,                2007                                                                                                                       |   |   | 3      |   |
|                                                                                                                                                                                                                                                 |   |   |   |   |
| Consolidated                Statements of Operations for the three months and nine months ended                September 30, 2008 and 2007 (Unaudited) and for the period from inception                (February 1, 2000) to September 30, 2008          |   |   | 4      |   |
|                                                                                                                                                                                                                                                 |   |   |   |   |
| Consolidated                Statements of Cash Flows for the nine months ended September 30,                2008 and                2007 (Unaudited) for the period from inception (February 1, 2000)                to                September 30, 2008 |   |   | 5      |   |
|                                                                                                                                                                                                                                                 |   |   |   |   |
| Notes                to Unaudited Consolidated Financial Statements                                                                                                                                                                                       |   |   | 6      |   |
|                                                                                                                                                                                                                                                 |   |   |   |   |
| Item                2. Management’s Discussion and Analysis of Financial Condition and Results                of Operations                                                                                                                         |   |   | 10     |   |
|                                                                                                                                                                                                                                                 |   |   |   |   |
| Item                3. Quantitative and Qualitative Disclosures about Market                Risk                                                                                                                                                          |   |   | 17     |   |
|                                                                                                                                                                                                                                                 |   |   |   |   |
| Item                4T. Controls and Procedures                                                                                                                                                                                                           |   |   | 18     |   |
|                                                                                                                                                                                                                                                      |   |   |   |   |
| PART                II. OTHER INFORMATION                                                                                                                                                                                                                 |   |   |   |   |
|                                                                                                                                                                                                                                                 |   |   |   |   |
| Item                1. Legal Proceedings                                                                                                                                                                                                                  |   |   | 18     |   |
|                                                                                                                                                                                                                                                 |   |   |   |   |
| Item                2. Unregistered Sales of Equity Securities and Use of                Proceeds                                                                                                                                                         |   |   | 18     |   |
|                                                                                                                                                                                                                                                      |   |   |   |   |
| Item                3. Defaults Upon Senior Securities                                                                                                                                                                                               |   |   | 19     |   |
|                                                                                                                                                                                                                                                      |   |   |   |   |
| Item                4. Submission of Matters to a Vote of Security Holders                                                                                                                                                                                |   |   | 19     |   |
|                                                                                                                                                                                                                                                 |   |   |   |   |
| Item                5. Other Information                                                                                                                                                                                                                  |   |   | 19     |   |
|                                                                                                                                                                                                                                                 |   |   |   |   |
| Item                6. Exhibits                                                                                                                                                                                                                           |   |   | 19     |   |
|                                                                                                                                                                                                                                                 |   |   |   |   |
| SIGNATURES                                                                                                                                                                                                                                                |   |   | 20     |   |

----

**Part      I.**
** **
**Financial      Information **

**Item      1. **
**Financial      Statements**

|                                                                                                                                                                                    |   | **September 30,** |        | **December 31,** |   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|------------------------|-------------|-----------------------|--------|
|                                                                                                                                                                                    |   | **2008**               |        | **2007**              |   |
|                                                                                                                                                                                    |   | **(Unaudited)**        |        |                  |   |
| ASSETS                                                                                                                                                                                  |   |                   |        |                  |   |   |   |
| Current                assets:                                                                                                                                                          |   |                   |        |                  |   |   |   |
| Cash                                                                                                                                                                                    |   | $                      | 48,293      |                  | $      | 122,810 |   |
| Inventory                                                                                                                                                                               |   |                   | 10,770      |                  |   | 11,425 |   |
| Prepaid                expenses                                                                                                                                                         |   |                   | 34,008      |                  |   | - |   |
| Total                current assets                                                                                                                                                     |   |                   | 93,071      |                  |   | 134,235 |   |
| Property                and equipment, net                                                                                                                                              |   |                   | 12,199      |                  |   | - |   |
| Goodwill                                                                                                                                                                                |   |                   | 2,397,749   |                  |   | - |   |
| Other                assets                                                                                                                                                             |   |                   | 8,133       |                  |   | 9,950 |   |
| TOTAL                ASSETS                                                                                                                                                             |   | $                      | 2,511,152   |                  | $      | 144,185 |   |
|                                                                                                                                                                                    |   |                   |        |                  |   |   |   |
| LIABILITIES                AND STOCKHOLDERS' EQUITY (DEFICIT)                                                                                                                           |   |                   |        |                  |   |   |   |
| Current                liabilities:                                                                                                                                                     |   |                   |        |                  |   |   |   |
| Accounts                payable                                                                                                                                                         |   | $                      | 165,642     |                  | $      | 22,496 |   |
| Accrued                expenses                                                                                                                                                         |   |                   | 796,789     |                  |   | 30,000 |   |
| Due                to officers                                                                                                                                                          |   |                   | 1,333,734   |                  |   | 1,944,414 |   |
| Other                loans payable                                                                                                                                                      |   |                   | 100,300     |                  |   | 100,000 |   |
| Total                current liabilities                                                                                                                                                |   |                   | 2,396,465   |                  |   | 2,096,910 |   |
|                                                                                                                                                                                    |   |                   |        |                  |   |   |   |
| Stockholders'                equity (deficit):                                                                                                                                          |   |                   |        |                  |   |   |   |
| Common                  stock, $0.001 par value, 2.0 billion shares authorized 197,776,482                  and 81,895,682 shares issued and outstanding,                  respectively |   |                   | 197,777     |                  |   | 81,896 |   |
| Additional                paid-in capital                                                                                                                                               |   |                   | 21,517,092  |                  |   | 18,074,473 |   |
| Deficit                accumulated during the development stage                                                                                                                         |   |                   | (21,600,182 | )                     |   | (20,109,094 | ) |
| Total                stockholders' equity (deficit)                                                                                                                                     |   |                   | 114,687     |                  |   | (1,952,725 | ) |
| TOTAL                LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)                                                                                                                     |   | $                      | 2,511,152   |                  | $      | 144,185 |   |

----

NUTRA      PHARMA CORP.

|                                                                      |   |                                                 |       |                                                |   |               |   |   |       | For                the |   |
|---------------------------------------------------------------------------|--------|------------------------------------------------------|------------|-----------------------------------------------------|--------|--------------------|--------|--------|------------|------------------------|--------|
|                                                                      |   |                                                 |       |                                                |   |               |   |   |       | Period From       |   |
|                                                                      |   |                                                 |       |                                                |   |               |   |   |       | February 1,       |   |
|                                                                      |   |                                                 |       |                                                |   |               |   |   |       | 2000                   |   |
|                                                                      |   |                                                 |       |                                                |   |               |   |   |       | (Inception)            |   |
|                                                                      |   |                                                 |       |                                                |   | Through            |   |
|                                                                      |   | Three Months Ended September 30, |       | Nine Months Ended September 30, |   | September 30, |   |
|                                                                      |   | 2007                                                 |       | 2008                                                |   | 2007               |   | 2008   |       | 2008                   |   |
| Sales                                                                     |   | $                                                    | -          |                                                | $      | 3,045              |   | $      | -          |                   | $      | 3,045 |   | $ | 23,245 |   |
|                                                                      |   |                                                 |       |                                                |   |               |   |   |       |                   |   |   |   |   |   |   |
| Cost                of sales                                              |   |                                                 | -          |                                                |   | 655                |   |   | -          |                   |   | 655 |   |   | 4,127 |   |
| Gross                profit                                               |   |                                                 | -          |                                                |   | 2,390              |   |   | -          |                   |   | 2,390 |   |   | 19,118 |   |
| Costs                and expenses:                                        |   |                                                 |       |                                                |   |               |   |   |       |                   |   |   |   |   |   |   |
| General                and administrative                                 |   |                                                 | 127,992    |                                                |   | 431,321            |   |   | 439,447    |                   |   | 950,838 |   |   | 7,894,231 |   |
| Research                and development                                   |   |                                                 | -          |                                                |   | -                  |   |   | -          |                   |   | - |   |   | 1,740,237 |   |
| General                and administrative - stock based compensation |   |                                                 | 599,375    |                                                |   | 75,000             |   |   | 603,050    |                   |   | 500,000 |   |   | 7,429,657 |   |
| Write-off                of advances to potential acquiree                |   |                                                 | -          |                                                |   | -                  |   |   | -          |                   |   | - |   |   | 629,000 |   |
| Finance                costs                                              |   |                                                 | -          |                                                |   | -                  |   |   | -          |                   |   | - |   |   | 786,000 |   |
| Interest                expense                                           |   |                                                 | 19,966     |                                                |   | 12,649             |   |   | 54,102     |                   |   | 42,640 |   |   | 438,699 |   |
| Amortization                of license agreement                          |   |                                                 | -          |                                                |   | -                  |   |   | -          |                   |   | - |   |   | 155,210 |   |
| Amortization                of intangibles                                |   |                                                 | -          |                                                |   | -                  |   |   | -          |                   |   | - |   |   | 656,732 |   |
| Losses                on settlements                                      |   |                                                 | -          |                                                |   | -                  |   |   | -          |                   |   | - |   |   | 1,261,284 |   |
| Write-down                of investment in subsidiary                     |   |                                                 | -          |                                                |   | -                  |   |   | -          |                   |   | - |   |   | 620,805 |   |
| Equity                in loss of unconsolidated subsidiary                |   |                                                 | -          |                                                |   | -                  |   |   | -          |                   |   | - |   |   | 853,540 |   |
| Write-off                of investment in Portage BioMed                  |   |                                                 | -          |                                                |   | -                  |   |   | -          |                   |   | - |   |   | 60,000 |   |
| Write-off                of investment in Xenacare                        |   |                                                 | -          |                                                |   | -                  |   |   | -          |                   |   | - |   |   | 175,000 |   |
| Net                gain from deconsolidation of Receptopharm              |   |                                                 | -          |                                                |   | -                  |   |   | (1,081,095 | )                      |   | - |   |   | (1,081,095 | ) |
| Total                costs and expenses                                   |   |                                                 | 747,333    |                                                |   | 518,970            |   |   | 15,504     |                   |   | 1,493,478 |   |   | 21,619,300 |   |
| Net                loss                                                   |   | $                                                    | (747,333   | )                                                   | $      | (516,580           | )      | $      | (15,504    | )                      | $      | (1,491,088 | ) | $ | (21,600,182 | ) |
| Per                share information - basic and diluted:            |   |                                                 |       |                                                |   |               |   |   |       |                   |   |   |   |   |   |   |
| Loss                per common share                                      |   | $                                                    | (0.01      | )                                                   | $      | (0.00              | )      | $      | (0.00      | )                      | $      | (0.01 | ) |   |   |   |
|                                                                      |   |                                                 |       |                                                |   |               |   |   |       |                   |   |   |   |   |   |   |
| Weighted                average common shares outstanding                 |   |                                                 | 79,655,954 |                                                |   | 188,838,473        |   |   | 75,502,385 |                   |   | 153,588,517 |   |   |   |   |

----

NUTRA      PHARMA CORP.

|                                                                 |   |                                                |     |               |   | For                the |   |
|----------------------------------------------------------------------|--------|-----------------------------------------------------|----------|--------------------|--------|------------------------|--------|
|                                                                 |   |                                                |     |               |   | Period From       |   |
|                                                                 |   |                                                |     |               |   | February 1,       |   |
|                                                                 |   |                                                |     |               |   | 2000                   |   |
|                                                                 |   |                                                |     |               |   | (Inception)            |   |
|                                                                 |   |                                                |     |               |   | Years Ended       |   |
|                                                                 |   |                                                |     | Through            |   |
|                                                                 |   | Nine Months Ended September 30, |     | September 30, |   |
|                                                                 |   | 2007                                                |     | 2008               |   | 2008                   |   |
|                                                                 |   |                                                |     |               |   |                   |   |
| Cash                flows from operating activities:                 |   |                                                |     |               |   |                   |   |   |   |   |
| Net                cash (used in) operating activities               |   | $                                                   | (630,825 | )                  | $      | (854,461               | )      | $ | (6,542,573 | ) |
| Cash                flows from investing activities:                 |   |                                                |     |               |   |                   |   |   |   |   |
| Cash                reduction due to deconsolidation of Infectech    |   |                                                | -        |               |   | -                      |   |   | (2,997 | ) |
| Cash                reduction due to deconsolidation of Receptopharm |   |                                                | -        |               |   | -                      |   |   | (1,754 | ) |
| Cash                acquired in acquisition of Infectech             |   |                                                | -        |               |   | -                      |   |   | 3,004 |   |
| Cash                acquired in acquisition of Receptopharm          |   |                                                |     |               |   | 40,444                 |   |   | 40,444 |   |
| Acquisition                of property and equipment                 |   |                                                | -        |               |   | -                      |   |   | (96,029 | ) |
| Loan                to Receptopharm                                  |   |                                                | -        |               |   | (300,000               | )      |   | (300,000 | ) |
| Investments                carried at cost                           |   |                                                | -        |               |   | -                      |   |   | (235,000 | ) |
| Net                cash (used in) investing activities               |   |                                                | -        |               |   | (259,556               | )      |   | (592,332 | ) |
|                                                                 |   |                                                |     |               |   |                   |   |   |   |   |
| Cash                flows from financing activities:                 |   |                                                |     |               |   |                   |   |   |   |   |
| Common                stock issued for cash                          |   |                                                | -        |               |   | 808,500                |   |   | 3,608,000 |   |
| Proceeds                from convertible loans                       |   |                                                | -        |               |   | -                      |   |   | 304,750 |   |
| Proceeds                from notes payable                           |   |                                                | -        |               |   | -                      |   |   | 100,000 |   |
| Loans                from stockholders, net of repayments            |   |                                                | 612,288  |               |   | 231,000                |   |   | 3,170,448 |   |
| Net                cash provided by financing activities             |   |                                                | 612,288  |               |   | 1,039,500              |   |   | 7,183,198 |   |
| Net                increase (decrease) in cash                       |   |                                                | (18,537  | )                  |   | (74,517                | )      |   | 48,293 |   |
| Cash                - beginning of period                            |   |                                                | 18,892   |               |   | 122,810                |   |   | - |   |
| Cash                - end of period                                  |   | $                                                   | 355      |               | $      | 48,293                 |   | $ | 48,293 |   |

----

Nutra      Pharma Corp.

----

| Net                losses included in the consolidated financial statements |   | $      | 4,056,095  |   |
|-----------------------------------------------------------------------------|--------|--------|------------|--------|
| Investment                advances and equity method losses                 |   |   | (2,975,000 | )      |
| Gain                on deconsolidation                                      |   | $      | 1,081,095  |   |

| Total                number of Nutra Pharma shares issued                  |   |   | 30,000,000 |   |
|----------------------------------------------------------------------------|--------|--------|------------|--------|
| Market                price of Nutra Pharma common stock on April 10, 2008 |   | $      | 0.035      |   |
| Value                of shares issued                                      |   | $      | 1,050,000  |   |
| Loan                to ReceptoPharm forgiven at closing                    |   |   | 300,000    |   |
| Liabilities                of ReceptoPharm assumed at closing              |   |   | 1,119,413  |   |
| Total                purchase cost to be allocated                         |   | $      | 2,469,413  |   |
|                                                                       |   |   |       |   |
| Allocation                of purchase cost:                                |   |   |       |   |
| Fair                value of Receptopharm assets at closing                |   | $      | 71,664     |   |
| Purchase                cost in excess of fair value of assets acquired    |   |   | 2,397,749  |   |
| Total                purchase cost                                         |   | $      | 2,469,413  |   |

----

----

|                                      |   | Numberof shares |      | Weightedaverageexercise                price |   | Weightedaveragefair value |   |
|-------------------------------------------|--------|----------------------|-----------|----------------------------------------------|--------|--------------------------------|--------|
|                                      |   |                 |      |                                         |   |                           |   |
| Balance                December 31, 2007  |   |                 | 3,000,000 |                                         | $      | 0.25                           |   | $ | 0.16 |   |
| Exercised                                 |   |                 | -         |                                         |   | -                              |   |   | - |   |
| Issued                                    |   |                 | -         |                                         |   | -                              |   |   | - |   |
| Forfeited                                 |   |                 | -         |                                         |   | -                              |   |   | - |   |
|                                      |   |                 |           |                                         |   |                                |   |   |  |   |
| Balance                September 30, 2008 |   |                 | 3,000,000 |                                         | $      | 0.25                           |   | $ | 0.16 |   |

**:**

| ExercisePrice |   | WeightedAverageNumberOutstanding |      | WeightedAverageContractualLife |   | WeightedAverageExercisePrice |   |
|---------------|--------|----------------------------------|-----------|--------------------------------|--------|------------------------------|--------|
|          |   |                             |      |                           |   |                         |   |
| $.20          |   |                             | 1,000,000 |                           |   | 2.50 years              |   | $ | .20 |   |
| $.27          |   |                             | 2,000,000 |                           |   | 2.25 years              |   | $ | .27 |   |
|          |   |                             | 3,000,000 |                           |   |                              |   |   |  |   |

----

**Item      2. **
**Management’s      Discussion and Analysis of Financial Condition and Results of Operations/Plan      of      Operations **

**Liquidity      and Capital Resources**

|   | · | Sell                  or dispose of our assets, if any; |
|--------|--------|---------------------------------------------------------|

|   | · | Pay                  our liabilities in order of priority, if we have available cash                  to pay                  such liabilities; |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | If                  any cash remains after we satisfy amounts due to our creditors,                  distribute                  any remaining cash to our shareholders in an amount equal to the                  net                  market value of our net assets; |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | File                  a Certificate of Dissolution with the State of California to dissolve                  our                  corporation and close our business; |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Make                  the appropriate filings with the Securities and Exchange Commission                  so                  that we will no longer be required to file periodic and other required                  reports with the Securities and Exchange Commission, if, in fact,                  we are a                  reporting company at that time; and |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Make                  the appropriate filings with the National Association of Security                  Dealers                  to effect a delisting of our common stock, if, in fact, our common                  stock                  is trading on the Over-the-Counter Bulletin Board at that                  time. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**Results      of Operations – Comparison of Three Month Periods ending September 30, 2007 and      September 30, 2008**

**Results      of Operations – Comparison of Nine Month Periods ending September 30, 2007 and      September 30, 2008**

**Off-Balance      Sheet Arrangements**

| · | an                obligation under a guarantee contract;                                                                                                                                                                                                        |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                            |
| · | a                retained or contingent interest in assets transferred to the                unconsolidated entity or similar arrangement that serves as credit,                liquidity or market risk support to such entity for such                assets; |
|   |                                                                                                                                                                                                                                                            |
| · | any                obligation, including a contingent obligation, under a contract that                would                be accounted for as a derivative instrument,                or;                                                                     |

----

| · | any                obligation, including a contingent obligation, arising out of a variable                interest in an unconsolidated entity that is held by us and material                to us                where such entity provides financing, liquidity, market risk or credit                risk support to, or engages in leasing, hedging or research and                development services with us. |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Plan      of Operations**

| Type                of Expenditure                                                                                             |   | Total Expenditure                  |    | Monthly Expenditure |   |
|--------------------------------------------------------------------------------------------------------------------------------|--------|----------------------------------------------|---------|--------------------------|--------|
|                                                                                                                           |   |                                         |    |                     |   |
| Salaries*                                                                                                                      |   | $                                            | 175,000 |                     | $      | 14,583 |   |
|                                                                                                                           |   |                                         |    |                     |   |   |   |
| Travel                related expenses for our Chief Executive Officer pertaining to research                and due diligence |   |                                         | 40,000  |                     |   | 3,333 |   |
|                                                                                                                           |   |                                         |    |                     |   |   |   |
| Professional                Fees -Legal and Accounting                                                                         |   |                                         | 165,000 |                     |   | 13,750 |   |
|                                                                                                                           |   |                                         |    |                     |   |   |   |
| Total                                                                                                                          |   | $                                            | 380,000 |                     | $      | 31,666 |   |

| Type                of Expenditure                                   |   | Total Expenditure                  |      | Monthly Expenditure |   |
|----------------------------------------------------------------------|--------|----------------------------------------------|-----------|--------------------------|--------|
|                                                                 |   |                                         |      |                     |   |
| Salaries                                                             |   | $                                            | 350,000   |                     | $      | 29,167 |   |
|                                                                 |   |                                         |      |                     |   |   |   |
| Clinical                Trial expenses                               |   |                                         | 1,045,000 |                     |   | 87,083 |   |
|                                                                 |   |                                         |           |                     |   |  |   |
| R                & D Expenses                                    |   |                                         | 394,000   |                     |   | 32,833 |   |
|                                                                 |   |                                         |           |                     |   |  |   |
| Cost                of raw materials and production                  |   |                                         | 236,000   |                     |   | 19,667 |   |
|                                                                 |   |                                         |      |                     |   |   |   |
| Operating                Expenses (Rent, Supplies, Utilities, etc..) |   |                                         | 50,000    |                     |   | 4,167 |   |
|                                                                 |   |                                         |      |                     |   |   |   |
| Total                                                                |   | $                                            | 2,075,000 |                     | $      | 172,917 |   |

----

| Type of Expenditure                            |   | TotalExpenditure |    | MonthlyExpenditure |   |
|--------------------------------------------------------------------|--------|------------------|---------|--------------------|--------|
|                                                               |   |             |    |               |   |
| Operating Expenses (Rent, supplies, utilities) |   | $                | 50,000  |               | $      | 4,167 |   |
| Salaries (President)                                |   |             | 70,000  |               |   | 5,833 |   |
| Total:                                                   |   | $                | 120,000 |               | $      | 10,000 |   |

|   | · | On                January 24, 2006, we obtained NanoLogix’s intellectual property pertaining                to the manufacture of test kits for the rapid isolation, detection                and                antibiotic sensitivity testing of certain microbacteria, which includes                reassignment to us of 11 key patents protecting the diagnostics test                kit                technology and NanoLogix licensing to us, and the remaining 18 patents                that protect the diagnostics test kit                technology. |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | In                February 2006, we completed the initial funding of ReceptoPharm in                the                amount of $2,000,000. |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | In                January 2006, we established Designer Diagnostics to sell NonTuberculois                Mycobacterium test kits. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------|

----

|   | · | Designer                Diagnostics held a Continuing Medical Education Seminar at the Mahatma                Gandhi Institute in India on March 24, 2006 during the World Stop                TB Day.                At that meeting, Designer Diagnostics officially began marketing                their                test kits for the rapid isolation, detection and antibiotic-sensitivity                testing of microbacteria. In March 2006, we made our first sales                of                Designer Diagnostics’ test kits. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | In                May 2006, ReceptoPharm received approval from the Medicines Health                and                Regulatory Agency (MHRA) for its application of human clinical trials                for                the treatment of Adrenomyeloneuropathy (AMN). The MHRA is the medical                regulatory agency within the British Department of                Health. |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | From                March and April of 2006, ReceptoPharm published two clinical trials                on the                use of their technology for the treatment of                pain. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | In                June 2006, ReceptoPharm published the results of their EAE rat model                of  MS, which showed that their drug, RPI-78M, had promising results                in an accepted animal model of the                disease. |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | In                October of 2006, ReceptoPharm received Ethics Committee approval                in the                United Kingdom to begin its Phase IIb human clinical trial for the                treatment of AMN. This approval allows for the late Phase II/early                Phase                III (Iib/IIIa) trial to begin. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | From                November 29, 2006 to December 2, 2006, ReceptoPharm presented their                analgesic research on RPI-78M at the International Conference on                Neurotoxins (ICoN) in Hollywood, Florida. |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | In                January of 2007, we completed a series of microarray studies with                various                companies that ReceptoPharm has agreements with pertaining to                ReceptoPharm’s anti-viral drug. The microarray studies indicated that the                exposure of healthy immune T-cells to our antiviral drugs activates                the                primary immune mechanisms. The expression of one such immune trigger,                interferon gamma, is increased by as much as 20 times, acting as                an                effective antiviral agent, but without the significant negative clinical                side effects of other interferon-based therapies. This may explain                the                broad antiviral activity observed with these types of agents. Based                upon                this data, these products could conceivably be used to substitute                for the                flu shot in winter or protect against other contagious viral diseases                when                vaccines are not readily available. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | In                January of 2007, Designer Diagnostics received positive results from                its                in-vitro analysis of its Tuberculosis (TB) test kit. Normal culturing                methods can take as long as 10 weeks to produce results, where Designer                Diagnostics test kits have shown similar results within 10                days. |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | In                January of 2007, ReceptoPharm began its Phase IIb human clinical                trial for                the treatment of AMN. |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | In                February of 2007, ReceptoPharm expanded their antiviral clinical                research                into Mexico and Peru where RPI-MN was used in early clinical studies.                ReceptoPharm seeks to conduct two Phase II antiviral trials each                with a                primary duration of 3-4 months. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | In                March of 2007, Designer Diagnostics engaged the U.S. Commercial Service                to                help build international sales of its diagnostic test                kits. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | On                March 7, 2007, ReceptoPharm’s signed a letter of intent to create a Joint                Venture with Nan gene Biotechnology, a Chinese biotech company. The                proposed joint venture will develop the antiviral drug, RPI-MN, for                the Chinese market. |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | · | In                March of 2007, ReceptoPharm published an article in the Critical                Reviews                in Immunology special conference issue. The article, entitled                “Alpha-Cobratoxin”, discussed Alpha-Cobratoxin as a possible therapy for                Multiple Sclerosis, reviews the literature leading to the development                for                this application, and discusses the background and reasoning behind                ReceptoPharm’s research on its treatment for Multiple Sclerosis                (MS). |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | On                March 27, 2007, we completed our first licensing payment on behalf                of                Designer Diagnostics to NanoLogix for the patents protecting Designer                Diagnostics’ test kits. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | On                April 11, 2007, ReceptoPharm filed a patent for method of treating                autoimmune diseases, including MS and Rheumatoid                Arthritis. |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | During                April 2007, ReceptoPharm completed its initial discussions with Zhong                Xin                Dong Tai Co., Ltd (“Nanogene Biotechnology”) to develop RPI-MN for the                China market. RPI-MN is ReceptoPharm’s drug candidate being researched for                the treatment of HIV/AIDS and other viral disorders. According to                a signed                Memorandum of Understand between ReceptoPharm and Nanogene Biotechnology.                ReceptoPharm will need to confirm safety and efficacy of RPI_MN by                completing pre-clinical studies at Soochow University located in                China.                Nanogene Biotechnology will provide the drug raw material and ReceptoPharm                will modify the products and provide the proper study protocols.                Upon                successful completion of the pre-clinical studies, ReceptoPharm and                Nanogene Biotechnology will proceed with clinical trials aimed at                gaining                full regulatory approval in China. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | On                May 2, 2007, Designer Diagnostics announced that it would conduct                clinical                trials for their Tuberculosis and NonTuberculois Mycobacterium diagnostic                test kits at the National Jewish Medical and Research Center in Denver,                Colorado. The purpose of the clinical trials is to validate the efficacy                of the test kits for use with Tuberculosis and Non-Tubernulosis                Mycobacterium patients as well as for environmental testing. The                clinical                trials for Designer Diagnostics are the final step required by the                FDA                prior to applying for FDA regulatory approval of the test kits. The                studies are ongoing with plans to complete testing throughout 2008. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | During                May 2007, Designer Diagnostics completed the upgrade of its Tuberculosis                diagnostic test kits enabling such the test kits to show more rapid                and                reliable results. |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | During                July 2007, ReceptoPharm successfully completed enrollment in its                phase llb                human clinical trial for the treatment of AMN. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | In                August of 2007, ReceptoPharm successful results on the use of their                technology for the treatment of pain. The latest data demonstrated                that                RPI-78 was as effective as morphine at blocking pain signals in that                part                of the brain that signals the presence of pain. It was also confirmed                that                the drug did not use an opioid mechanism. Moreover, the duration                of                RPI-78’s effect was superior to                morphine’s. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | In                November 2007, the Designer Diagnostics test kit technology was showcased                at the 38th Union World Conference on Lung Health in South Africa.                The                test kits were used to isolate NTM from clinical samples of 300 AIDS                patients and for the first time ever on the Indian subcontinent,                M.                Wolinskyi was successfully isolated in clinical samples. In addition,                these test kits were also used for the first time to isolate NTM                from soil                and water samples collected from the environment of patients with                NTM                disease. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | In                November 2007, Designer Diagnostics was featured in an article published                in the International Journal of TB and Lung Diseases. The article,                which                was authored by leading NonTuberculous Mycobacterium (NTM) research                scientist, Dr. Rahul Narang, covered Designer Diagnostics’ paraffin                culture technology to isolate NTM. |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | · | In                December 2007, ReceptoPharm successfully completed its six-month                patient                crossover in the Phase IIb/IIIa clinical trial for the treatment                of                Adrenomyeloneuropathy (AMN). |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | On                December 27, 2007 the Company expanded its licensing agreement with                NanoLogix, Inc., to include intellectual property for the use of                testing                the environment for NonTuberculous Mycobacterium                (NTM). |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | In                February 2008, Designer Diagnostics started marketing the first-ever                environmental test kit for the detection of Nontuberculous Mycobacteria                (NTM) in water and soil. |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | On                April 10, 2008, we completed the acquisition of ReceptoPharm through                our                purchase of their remaining 61.9% interest. ReceptoPharm is now our                wholly                owned subsidiary and will act as our Drug Discovery division.                                                                  |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                                                                                                                                                                                                             |
|   | · | On                May 19, 2008, we announced today that ReceptoPharm, Inc. had received                approval from the Florida Department of Agriculture and Consumer                Services                to conduct trials of its leading antiviral drug candidate, RPI-MN,                as a                treatment for Feline Leukemia Virus (FeLV). |
|   |   |                                                                                                                                                                                                                                                                                                                                                             |
|   | · | On                July 19, 2008, we announced the successful completion of ReceptoPharm’s                Phase IIb/IIIa clinical trial of its leading drug candidate for                neurological and autoimmune disorders, RPI-78M, as a treatment for                Adrenomyeloneuropathy (AMN).                                                     |
|   |   |                                                                                                                                                                                                                                                                                                                                                             |
|   | · | On                August 6, 2008, we announced that ReceptoPharm had renewed its                collaborative agreement with the Centers for Disease Control and                Prevention (CDC) to study RPI-78M and RPI-MN as a possible therapy                for                Rabies.                                                                     |
|   |   |                                                                                                                                                                                                                                                                                                                                                             |
|   | · | On                August 14, 2008, we announced initial positive safety data from                ReceptoPharm’s Phase IIb/IIIa clinical study of RPI-78M for treating                Adrenomyeloneuropathy (AMN).                                                                                                                                          |

*Designer      Diagnostics, Inc.*

| · | Hospitals; |
|--------|------------|

| · | Pharmaceutical                companies; |
|--------|------------------------------------------|

| · | Biotechnology                companies; |
|--------|-----------------------------------------|

| · | Medical                device distributors; |
|--------|---------------------------------------------|

| · | Governmental                organizations;                                                                         |
|--------|--------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                               |
| · | Environmental                testing facilities; and                                                               |
|   |                                                                                                               |
| · | Government                water and soil testing facilities at the local, state and federal                levels. |

----

*ReceptoPharm*

| · | Recruitment                of 20 patients with AMN; |
|--------|-----------------------------------------------------|

| · | Administering                ReceptoPharm’s AMN drug under development;                and |
|--------|--------------------------------------------------------------------------------------------------|

| · | Monitoring                patients throughout a 15-month                protocol. |
|--------|-----------------------------------------------------------------------------------|

**Item      3. Quantitative and Qualitative Disclosures About Market Risk**

----

**Item      4T. Controls and Procedures**

**PART      II.**
**OTHER      INFORMATION**

**Item      1.**
**Legal      Proceedings **

**Item        2. Unregistered Sales of Equity Securities and Use of        Proceeds**

|  | · | We                    are not and were not a blank check company at the time of the                    offer or                    sale; |
|--|--------|------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | The                    investors had business experience and were accredited investors                    as defined                    by Rule 501 of Regulation D of the                    Act; |
|--|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | All                    offers and sales of the investment were made privately and no                    party                    engaged in any general solicitation or advertising of the proposed                    investment; |
|--|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | Each                    investor had a preexisting social, personal or business relationship                    with                    us and members of our                    management; |
|--|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | The                  investors were provided with all information sufficient to allow                  them to                  make an informed investment                  decision; |
|--|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | The                    investors had the opportunity to inspect our books and records                    and to                    verify statements made to induce them to                    invest; |
|--|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | The                    securities representing the investment were issued with a restrictive                    legend indicating the securities represented by the certificate                    have not                    been registered; and |
|--|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | · | No                    party received any transaction-based compensation such as commissions                    in                    regard to locating any investor for the                    venture |
|--|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**Item      3. **
**Defaults      Upon Senior Securities**

**Item      4. **
**Submission      of Matters to a Vote of Security Holders **

**Item      5.**
**Other      Information **

**Item      6.**
**Exhibits      **

| Exhibit No. |   | Title                                                                                                                                                                                                                                      |
|------------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|             |   |                                                                                                                                                                                                                                       |
| 31.1             |   | Certification of                Chief Executive Officer and Chief Financial Officer pursuant to Section                302 of the Sarbanes-Oxley Act of 2002.                                                                         |
|             |   |                                                                                                                                                                                                                                       |
| 32.1             |   | Certification                of Chief Executive Officer and Chief Financial Officer pursuant to                18                U.S.C. Section 1350, as adopted pursuant to Section 906 of the                Sarbanes-Oxley Act of 2002. |

----

**SIGNATURES**

| Dated:                November 19, 2008                                                                                              |   |   |   |
|--------------------------------------------------------------------------------------------------------------------------------------|--------|--------|--------|
|                                                                                                                                 |   |   |   |
| NUTRA                PHARMA CORP.                                                                                                    |   |   |   |
| Registrant                                                                                                                           |   |   |   |
|                                                                                                                                 |   |   |   |
| /s/ Rik                J. Deitsch                                                                                               |   |   |   |
| Rik                J. Deitsch                                                                                                        |   |   |   |
| Chief                Executive Officer/Principal Financial OfficerChief                Financial Officer/Principal Financial Officer |   |   |   |

----